GERN - NASDAQ
Geron Corporation
$1.22
+4.3%Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
At a Glance
Live SnapshotGeron Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Geron Corporation Income Statement
GERN • NASDAQ
| Geron Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
183.9M | 77M | 237K | 596K | 1.4M | 253K | 460K | 1.1M | 1.1M | 6.2M | 36.4M | 1.2M | 1.3M | 2.7M | 2.4M | 3.6M | 1.7M | 2.8M | 7.6M | 3.3M | |
GROSS PROFIT | ||||||||||||||||||||
(4.7M) | (1.3M) | (0.0) | (0.0) | (0.0) | (50.1M) | (51.3M) | (12.7M) | (8.4M) | (14.7M) | (9.6M) | (8.9M) | (9.1M) | (25.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
179.1M | 75.7M | 237K | 596K | 1.4M | -49.8M | -50.8M | -11.7M | -7.4M | -8.5M | 26.8M | -7.7M | -7.9M | -22.5M | 2.4M | 3.6M | 1.7M | 2.8M | 7.6M | 3.3M | |
OPERATING INCOME | ||||||||||||||||||||
(233M) | (249.5M) | (194.2M) | (139.1M) | (115.4M) | (27.1M) | (73M) | (32.1M) | (30.3M) | (36.8M) | (35.6M) | (37.5M) | (38.8M) | (71.8M) | (93.1M) | (79.7M) | (72M) | (69.8M) | (70.5M) | (50.6M) | |
(159.3M) | (145.7M) | (69.1M) | (43.6M) | (29.7M) | (27.1M) | (20.9M) | (18.7M) | (19.3M) | (18.8M) | (17.8M) | (16.8M) | (15.6M) | (20.4M) | (23.8M) | (18M) | (14.3M) | (16.2M) | (15.8M) | (9.4M) | |
(73.7M) | (103.7M) | (125M) | (95.5M) | (85.7M) | (51.5M) | (52.1M) | (13.4M) | (11M) | (18M) | (17.8M) | (20.7M) | (23.2M) | (51.4M) | (69.3M) | (61.7M) | (57.6M) | (53.7M) | (54.6M) | (41.2M) | |
-53.8M | -173.7M | -193.9M | -138.6M | -114M | -76.9M | -72.5M | -31.1M | -29.3M | -30.6M | -559K | -36.3M | -39M | -71.8M | -96.1M | -111.2M | -70.2M | -67M | -62.8M | -47.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(32.7M) | (18.5M) | (8.3M) | (6.9M) | (3.7M) | (760K) | (0.0) | (0.0) | (0.0) | (83K) | (88K) | (82K) | (56K) | (233K) | (237K) | (98K) | (143K) | (93K) | (102K) | (130K) | |
-14.5M | 1.1M | 9.8M | -4.4M | -3.2M | 1.1M | 4.2M | 3.3M | 1.4M | 1.1M | 589K | 291K | 895K | 2.9M | 787K | 1.9M | 1.2M | 5.4M | 10.7M | 8.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -51.5M | -69K | -154K | (0.0) | (0.0) | (1.3M) | (0.0) | (0.0) | (5.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-31.9M | -840K | 9.8M | -3.4M | -2.1M | 1.3M | 4M | 4.1M | 1.3M | 1.1M | 605K | 642K | 579K | 2.9M | -737K | -210K | 50K | 5M | 26.1M | 16M | |
-85.8M | -174.6M | -184.1M | -141.9M | -116.1M | -75.6M | -68.5M | -27M | -27.9M | -29.5M | 46K | -35.7M | -38.4M | -68.9M | -96.9M | -111.4M | -70.2M | -62M | -36.7M | -31.4M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (35K) | (56K) | -597K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-85.8M | -174.6M | -184.1M | -141.9M | -116.1M | -75.6M | -63.6M | -27M | -27.9M | -29.5M | 46K | -35.7M | -38.4M | -68.9M | -96.9M | -111.4M | -70.2M | -62M | -36.7M | -31.4M |
SEC Filings
GERN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your GERN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.